Icotinib is a primary research drug in China, and studies have shown that it is as effective as the other EGFR‐TKI first‐generation drugs.6, 7, 8 Compared with cisplatin, nedaplatin, a cisplatin derivative, has fewer toxic effects, higher response rate and longer overall survival, especially in patients with squamous carcinoma.9, 10 If WFO was able to output these two alternative treatments as “recommended” or “for consideration,” the overall consistency could be elevated from 73.3% to 90.3%. The gene discussed is EGFR; the disease is squamous cell carcinoma.